Krystal Biotech
Makes a meaningful difference in the lives of underserved patient populations suffering from debilitating skin diseases.
Launch date
Employees
Market cap
CAD7.9b
Enterprise valuation
CAD7.1b (Public information from Sep 2024)
Share price
$184.48 KRYS
Pittsburgh Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 50.7m | 294m | 492m | 656m |
| % growth | - | - | - | - | 479 % | 68 % | 33 % |
| EBITDA | (31.1m) | (65.3m) | (111m) | (69.6m) | 62.5m | 163m | 282m |
| % EBITDA margin | - | - | - | (137 %) | 21 % | 33 % | 43 % |
| Profit | (32.2m) | (69.6m) | (140m) | 10.9m | 76.4m | 198m | 296m |
| % profit margin | - | - | - | 22 % | 26 % | 40 % | 45 % |
| EV / revenue | - | - | - | 57.3x | 17.1x | 9.8x | 6.9x |
| EV / EBITDA | -29.5x | -20.0x | -15.0x | -41.7x | 80.4x | 29.7x | 16.0x |
| R&D budget | 17.9m | 27.9m | 42.5m | 46.4m | - | - | - |
| R&D % of revenue | - | - | - | 92 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$7.0m | Early VC | ||
| N/A | $45.5m | IPO | |
| N/A | $10.0m | Growth Equity VC | |
| N/A | $100m | Post IPO Equity | |
* | N/A | $200m | Post IPO Equity |
* | $160m | Private Placement VC | |
| Total Funding | CAD241m | ||
Related Content
Recent News about Krystal Biotech
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.